Developer docs
API playgroundTry for free, no card

Search company profiles

Evidity Health Capital

Full company profile

uuid0009hv4

Namestring
Evidity Health Capital
Legal namestring
Evidity Capital, LLC
Websiteurl
evidity.com
Company typeenum
Private
Founded yearint
2014
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, growth equity firm, healthcare venture capital, medical device investment, late-stage growth capital
Industry1 code
1Healthcare & Life Sciences Growth Equity
CodeFSANACABPrimaryYes
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Venture Capital
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Fund Management
TypeSubscription Recurring
Description

Evidity generates revenue through managing assets for leading, innovative, and transformative healthcare companies. As an Exempt Reporting Adviser with the SEC, the firm earns management fees and carried interest from its investment activities.

evidity.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Evidity Health Capital is a late-stage venture capital and growth equity firm that invests in private medical technology companies with commercialized products and US regulatory clearance. The firm provides growth capital (minimum $5M) to medtech, in vitro diagnostics, and digital health companies seeking to achieve profitability, combined with active board participation and business-building expertise.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Multiple successful exits including Biotheranostics ($230M to Hologic), Cardiva Medical ($475M+ to Haemonetics)
+1 more record
Product and service2 records
1Growth Capital Investment
CategoryGrowth Equity Investment
2Portfolio Company Board and Operational Support
CategoryInvestment Support Services
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1KT Corporation
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-08
Description

Commercial partnership with Sonde Health for voice-based businesses including call centers, AI voice assistants for health monitoring, digital therapeutics and telemedicine in Asia.

2BD (Becton, Dickinson and Company)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-10-18
Description

Co-exclusive commercial agreement with Magnolia Medical Technologies. BD and Magnolia co-sell and co-market Steripath Initial Specimen Diversion Device platforms, complementing BD specimen collection portfolio.

3GN Group
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-18
Description

Integrating Sonde Health Mental Fitness vocal biomarker into hearing products. Also developing MCI vocal biomarker.

4Koye Pharmaceuticals
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Developing COPD vocal biomarker and expanded partnership to develop novel mental health vocal biomarker for deployment in India.

5Qualcomm
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-08
Description

Integrated Sonde Health vocal biomarkers into mobile device chipsets; extended relationship to include wearable chipsets.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Accelmed Partners
TypeDirect peer
Description

Healthcare-dedicated growth equity and venture capital firm focused on commercial-stage medical device and digital health companies. Co-invested with Evidity in GT Medical Technologies, making it a directly comparable late-stage healthcare investor.

2MVM Partners
TypeDirect peer
Description

Healthcare-focused growth equity firm investing in commercial-stage medical technology, diagnostics, and specialty pharma companies. Participated alongside Evidity in GT Medical's Series D, indicating overlapping deal flow and strategy.

3Gilde Healthcare
TypeDirect peer
Description

European-headquartered healthcare growth equity and venture capital investor with US presence. Co-invested with Evidity in GT Medical, making it a directly comparable medtech-focused growth equity peer.

4H.I.G. Capital
TypeDirect peer
Description

Large alternative investment firm with a dedicated healthcare/life sciences practice. Co-invested with Evidity in Augmedics' Series D, indicating parallel late-stage medtech investing.

5Revival Healthcare Capital
TypeDirect peer
Description

Specialized medical device growth equity firm focused on commercial-stage companies. Co-invested with Evidity in Augmedics, supporting a directly comparable medtech growth equity thesis.

6Versant Ventures
TypeBroad incumbent
Description

Larger, established healthcare-dedicated venture capital firm with broader stage and sector coverage including medtech, biopharma, and healthcare services. Operates in the same vertical as Evidity but at a larger scale and broader thesis.

7OrbiMed
TypeBroad incumbent
Description

Large healthcare-dedicated investment firm covering venture, growth equity, and public equities across medical devices, biopharma, and diagnostics. Comparable as a much larger incumbent in the same healthcare growth equity space.

8New Enterprise Associates (NEA)
TypeBroad incumbent
Description

Large multi-stage venture capital firm with a significant healthcare practice investing in medical devices, diagnostics, and digital health. Broad incumbent with overlapping sector exposure but at much larger fund sizes.

9HealthCare Royalty Partners
TypeBroad incumbent
Description

Healthcare-focused investment firm with strategies spanning growth equity, royalties, and structured finance across medtech and biopharma. Comparable as a broader healthcare investment platform.

10CPMG
TypeRegional player
Description

Private investment firm focused on commercial-stage medical technology and healthcare companies. Led Augmedics' Series D alongside Evidity, making it a directly comparable medtech-focused growth equity peer.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment24 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Evidity Health Capital

Healthcare Venture Capitalevidity.com

Evidity Health Capital firmographics

Firmographics
Name
Evidity Health Capital
Legal name
Evidity Capital, LLC
Website
https://evidity.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Evidity Health Capital industry classification

Industry
Product category
Healthcare Venture Capital
NAICS
Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394)
SIC
Investment Advice (6282)
akta.pro primary industry
Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

  • Venture capital investing
  • Growth equity firm
  • Healthcare venture capital
  • Medical device investment
  • Late-stage growth capital

Where Evidity Health Capital is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Evidity Health Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Fund Management: Evidity generates revenue through managing assets for leading, innovative, and transformative healthcare companies. As an Exempt Reporting Adviser with the SEC, the firm earns management fees and carried interest from its investment activities.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Evidity Health Capital product offering

Product offering

Core offering

Evidity Health Capital is a late-stage venture capital and growth equity firm that invests in private medical technology companies with commercialized products and US regulatory clearance. The firm provides growth capital (minimum $5M) to medtech, in vitro diagnostics, and digital health companies seeking to achieve profitability, combined with active board participation and business-building expertise.

Differentiator

Problem solved

Functional benefit

Products and services

  • Growth Capital Investment
  • Portfolio Company Board and Operational Support

Quantifiable outcome

  • Multiple successful exits including Biotheranostics ($230M to Hologic), Cardiva Medical ($475M+ to Haemonetics)
  • +1 more outcomes

Companies that use Evidity Health Capital

Customer profile

Named customers6 records

Segments1 record

Ideal customer profiles1 record

Evidity Health Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Evidity Health Capital partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • KT CorporationcoreStrategic or Co-development Partner · 8 December 2022Commercial partnership with Sonde Health for voice-based businesses including call centers, AI voice assistants for health monitoring, digital therapeutics and telemedicine in Asia.
  • BD (Becton, Dickinson and Company)coreChannel Partner/ Reseller/ Distributor · 18 October 2022Co-exclusive commercial agreement with Magnolia Medical Technologies. BD and Magnolia co-sell and co-market Steripath Initial Specimen Diversion Device platforms, complementing BD specimen collection portfolio.
  • GN GroupcoreStrategic or Co-development Partner · 18 January 2022Integrating Sonde Health Mental Fitness vocal biomarker into hearing products. Also developing MCI vocal biomarker.
  • Koye PharmaceuticalsminorStrategic or Co-development Partner · 1 January 2022Developing COPD vocal biomarker and expanded partnership to develop novel mental health vocal biomarker for deployment in India.
  • QualcommcoreStrategic or Co-development Partner · 8 July 2021Integrated Sonde Health vocal biomarkers into mobile device chipsets; extended relationship to include wearable chipsets.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Evidity Health Capital competitors and assessment

Company assessment

Direct peers

  • Accelmed Partners: Healthcare-dedicated growth equity and venture capital firm focused on commercial-stage medical device and digital health companies. Co-invested with Evidity in GT Medical Technologies, making it a directly comparable late-stage healthcare investor.
  • MVM Partners: Healthcare-focused growth equity firm investing in commercial-stage medical technology, diagnostics, and specialty pharma companies. Participated alongside Evidity in GT Medical's Series D, indicating overlapping deal flow and strategy.
  • Gilde Healthcare: European-headquartered healthcare growth equity and venture capital investor with US presence. Co-invested with Evidity in GT Medical, making it a directly comparable medtech-focused growth equity peer.
  • H.I.G. Capital: Large alternative investment firm with a dedicated healthcare/life sciences practice. Co-invested with Evidity in Augmedics' Series D, indicating parallel late-stage medtech investing.
  • Revival Healthcare Capital: Specialized medical device growth equity firm focused on commercial-stage companies. Co-invested with Evidity in Augmedics, supporting a directly comparable medtech growth equity thesis.

Broad incumbents

  • Versant Ventures: Larger, established healthcare-dedicated venture capital firm with broader stage and sector coverage including medtech, biopharma, and healthcare services. Operates in the same vertical as Evidity but at a larger scale and broader thesis.
  • OrbiMed: Large healthcare-dedicated investment firm covering venture, growth equity, and public equities across medical devices, biopharma, and diagnostics. Comparable as a much larger incumbent in the same healthcare growth equity space.
  • New Enterprise Associates (NEA): Large multi-stage venture capital firm with a significant healthcare practice investing in medical devices, diagnostics, and digital health. Broad incumbent with overlapping sector exposure but at much larger fund sizes.
  • HealthCare Royalty Partners: Healthcare-focused investment firm with strategies spanning growth equity, royalties, and structured finance across medtech and biopharma. Comparable as a broader healthcare investment platform.

Regional players

  • CPMG: Private investment firm focused on commercial-stage medical technology and healthcare companies. Led Augmedics' Series D alongside Evidity, making it a directly comparable medtech-focused growth equity peer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Evidity Health Capital social profiles

Digital presence

Evidity Health Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Evidity Health Capital leadership team

Management profile

Number of profiles

Profiles4 records

Evidity Health Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Evidity Health Capital M&A and investment

M&A and investment

M&A

Investments24 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evidity Health Capital

What does Evidity Health Capital do?

Evidity Health Capital is a late-stage venture capital and growth equity firm that invests in private medical technology companies with commercialized products and US regulatory clearance. The firm provides growth capital (minimum $5M) to medtech, in vitro diagnostics, and digital health companies seeking to achieve profitability, combined with active board participation and business-building expertise.

Is Evidity Health Capital a public or private company?

Evidity Health Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Evidity Health Capital founded?

Evidity Health Capital was founded in 2014. It employs 1 to 10 people.

Where is Evidity Health Capital based?

Evidity Health Capital is headquartered in New York, United States, in the North America region.

How does Evidity Health Capital make money?

One revenue line is on record: fund Management.

Who are Evidity Health Capital's main competitors?

Direct peers on record are Accelmed Partners, MVM Partners, Gilde Healthcare, H.I.G. Capital and Revival Healthcare Capital. Broad incumbents are Versant Ventures, OrbiMed, New Enterprise Associates (NEA) and HealthCare Royalty Partners. CPMG is listed as a regional player.

Does Evidity Health Capital have an API?

No public API is recorded for Evidity Health Capital.

What industry is Evidity Health Capital in?

Evidity Health Capital's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MassDeviceGT Medical completes oversubscribed $100M Series EGT Medical Technologies announced the closing of an oversubscribed $100 million Series E equity financing round led by new investor Viking Global Investors, with participation from existing investors MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners, and FemHealth Ventures. The Arizona-based company will use the proceeds to support its GammaTile radiation therapy device, which delivers immediate targeted radiation during brain tumor removal surgery, and to accelerate its ROADS and BRIDGES clinical trials. The CEO described the financing as validation of GammaTile's potential to become a standard of care treatment for operable brain tumors.PR NewswireGT Medical Technologies Completes Oversubscribed $100 Million Series E Equity Financing to Advance Commercial Treatment for Patients with Operable Brain TumorsGT Medical Technologies closed a $100 million oversubscribed Series E equity financing round led by new investor Viking Global Investors, with participation from existing investors MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners and FemHealth Ventures. The funding will accelerate commercial and operational investments for GammaTile, the company's FDA-cleared bioresorbable radiotherapy implant, following positive data from the ROADS randomized controlled trial showing a 93% reduction in tumor recurrence risk and 41% reduction in death risk at 12 months compared to standard of care. Proceeds will also support the ongoing BRIDGES clinical trial for newly diagnosed glioblastoma patients.Mpo-magGT Medical Tech Pockets $100M in Oversubscribed Series EGT Medical Technologies closed an oversubscribed $100 million Series E financing led by Viking Global Investors. The funds will support commercial and operational initiatives after ROADS trial data showed a 93% reduction in tumor reoccurrence and 41% in death at 12 months. Proceeds will also expand the BRIDGES trial for glioblastomas.FinSMEsGT Medical Technologies Raises $100M in Series E FundingGT Medical Technologies raised $100M in Series E funding led by Viking Global Investors. The company will use the funds to accelerate commercial and operational initiatives and support its BRIDGES RCT in glioblastoma patients. The company develops GammaTile, a bioresorbable radioactive tile for immediate targeted radiation.MassDeviceGT Medical raises $37M to advance bioresorbable radiation tileGT Medical Technologies completed a $37 million first close of its Series D financing round to support clinical studies and commercialization of its GammaTile bioresorbable radiation implant. The funding, led by Evidity Health Capital with participation from Accelmed Partners and existing investors, will specifically advance the ROADS and GESTALT clinical trials for brain metastases and glioblastomas.PR NewswireGT Medical Technologies Raises $37 Million in Series D to Advance the Expansion of GammaTile® in the U.S. for Patients with Operable Brain TumorsGT Medical Technologies announced the completion of a $37 million first close for its Series D financing round, led by Evidity Health Capital with participation from Accelmed Partners and existing investors. The funds will accelerate the ROADS and GESTALT clinical studies for GammaTile while supporting the commercialization of the FDA-cleared bioresorbable radiotherapy implant. GT MedTech anticipates completing a second close of the round in Q1 2025 to expand clinical and commercial operations.PR NewswireEvidity Health Capital's Adam Lessler, MD named PartnerAdam Lessler, MD has been named Partner and appointed to the Management Committee at Evidity Health Capital, a late-stage venture capital and growth equity firm focused on medtech investments. In this new role, Lessler will continue overseeing investment sourcing and evaluation while taking on additional leadership responsibilities at the firm. Lessler brings nearly fifteen years of healthcare industry experience, including prior roles at McKinsey & Company and Goldman Sachs, as well as emergency medicine residency training.BioSpacePreludeDx™ Closes $20 Million in Funding to Advance Growth Initiatives and Development of Its Precision Medicine PortfolioPrelude Corporation closed a $20 million funding round led by Evidity Health Capital to advance its precision medicine portfolio and commercial expansion. The proceeds will support the growth of its DCISionRT diagnostic test for early-stage breast cancer, with Evidity Health Capital's Managing Director joining the company's board.